Literature DB >> 12649183

Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy.

Aaron D Schimmer1, Irene Munk Pedersen, Shinichi Kitada, Emel Eksioglu-Demiralp, Mark D Minden, Ryan Pinto, Ken Mah, Michael Andreeff, Youngsoo Kim, Won Suk Suh, John C Reed.   

Abstract

Defects in apoptosis mechanisms contribute to chemoresistance in malignancy. However, correlations of apoptosis-regulating proteins with clinical outcome in cancer patients are variable, presumably reflecting the difficulty of using static tests of gene expression in a scenario influenced by a dynamic interplay of multiple pro- and antiapoptotic molecules. Therefore, we assessed the functional integrity of apoptosis pathways in intact primary leukemia cells and correlated the functional status of these pathways with clinical outcome. Active apoptogenic proteins were introduced into primary leukemia cells by electroporation followed by measurement of active caspases by flow cytometric techniques. Cytochrome c was introduced to activate the intrinsic (mitochondrial) pathway, whereas caspase-8 was introduced to activate the extrinsic (death receptor) pathway. In a series of 24 patients with acute myeloid leukemia, 79% had a block in at least one pathway, indicating that defects in caspase activation mechanisms are common in patients with leukemia. Simultaneous blocks in both pathways correlated with chemoresistant disease (92% of patients with chemoresistant disease versus 33% of patients with chemosensitive disease; P = 0.005) and decreased overall patient survival (35% versus 89% 1-year survival; P = 0.02). Simultaneous blockage of the intrinsic and extrinsic pathways could be explained by a defect located at a point of convergence of the two pathways, probably related to overexpression of endogenous inhibitors of the effector-caspases, rather than decreased levels of these proteases. This study supports the importance of apoptosis pathways in determining response to chemotherapy and suggests that functional defects in caspase activation are prognostic in patients with leukemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649183

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

3.  Doxorubicin resistance mediated by cytoplasmic macrophage colony-stimulating factor is associated with switch from apoptosis to autophagic cell death in MCF-7 breast cancer cells.

Authors:  Mengxia Zhang; Hailiang Zhang; Fan Tang; Yuhua Wang; Zhongcheng Mo; Xiaoyong Lei; Shengsong Tang
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-24

4.  Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.

Authors:  Husheng Ding; Jennifer S McDonald; Seongseok Yun; Paula A Schneider; Kevin L Peterson; Karen S Flatten; David A Loegering; Ann L Oberg; Shaun M Riska; Shengbing Huang; Frank A Sinicrope; Alex A Adjei; Judith E Karp; X Wei Meng; Scott H Kaufmann
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

5.  Activation of dual apoptotic pathways in human melanocytes and protection by survivin.

Authors:  Tong Liu; Diana Biddle; Adrianne N Hanks; Brook Brouha; Hui Yan; Ray M Lee; Sancy A Leachman; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2006-05-25       Impact factor: 8.551

6.  Harnessing the cell death pathway for targeted cancer treatment.

Authors:  Christina K Speirs; Misun Hwang; Sungjune Kim; Weier Li; Sophia Chang; Vinod Varki; Lauren Mitchell; Stephen Schleicher; Bo Lu
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

7.  Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.

Authors:  Bing Z Carter; Marcela Gronda; Zhiliang Wang; Kate Welsh; Clemencia Pinilla; Michael Andreeff; Wendy D Schober; Adel Nefzi; Gregory R Pond; Imtiaz A Mawji; Richard A Houghten; John Ostresh; Joseph Brandwein; Mark D Minden; Andre C Schuh; Richard A Wells; Hans Messner; Kathy Chun; John C Reed; Aaron D Schimmer
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

8.  Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response.

Authors:  Bryan J Schneider; Manish A Shah; Kelsey Klute; Allyson Ocean; Elizabeta Popa; Nasser Altorki; Michael Lieberman; Andrew Schreiner; Rhonda Yantiss; Paul J Christos; Romae Palmer; Daoqi You; Agnes Viale; Pouneh Kermani; Joseph M Scandura
Journal:  Clin Cancer Res       Date:  2016-11-10       Impact factor: 12.531

9.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Authors:  Jürgen Sonnemann; Linn Dreyer; Maite Hartwig; Chithra D Palani; Le Thi Thu Hong; Ulrike Klier; Barbara Bröker; Uwe Völker; James F Beck
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

10.  The antitumor immune response in HER-2 positive, metastatic breast cancer patients.

Authors:  Zorica D Juranic; Zora Neskovic-Konstantinovic; Tatjana P Stanojkovic; Zeljko Zizak; Tatjana Srdic; Nevenka Stanojevic-Bakic; Dusanka Milosevic; Danica Jovanovic
Journal:  J Transl Med       Date:  2005-03-22       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.